EuroBiotech: More Articles of Note

(Image: Pixabay)

> Ablynx dosed the first patient in a Japanese phase 2a trial of its treatment for respiratory syncytial virus. Data from the study are due in the second half of next year. Release 

> MyBiotics entered into another licensing agreement with Ferring. The deal covers microbiome therapies. Statement

> Artios Pharma in-licensed a DNA nuclease-targeting cancer drug. The asset is the first picked up by Artios through its research collaboration with Masaryk University in the Czech Republic. Release

Free Daily Newsletter

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> A phase 2 trial of Sanfit’s treatment of calciphylaxis met its primary and secondary endpoints. The finding suggests SNF472 may aid wound healing and reduce pain in patients with the rare disease. Statement 

> BioMedPartners closed a CHF 100 million ($106 million) investment fund. The Swiss VC shop will use the money to back 12 to 15 early to midstage companies in its home country and neighboring nations. Release (PDF)

> Summit Therapeutics expanded enrollment in its phase 2 Duchenne muscular dystrophy trial. Enrollment is now open to patients who participated in the phase 1 study but fell foul of the more restrictive inclusion/exclusion criteria of the subsequent trial. Statement